nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—breast cancer	0.536	1	CbGaD
Methylnaltrexone—CYP2D6—Idarubicin—breast cancer	0.0592	0.414	CbGbCtD
Methylnaltrexone—CYP2D6—Vinorelbine—breast cancer	0.0289	0.202	CbGbCtD
Methylnaltrexone—CYP2D6—Tamoxifen—breast cancer	0.0261	0.183	CbGbCtD
Methylnaltrexone—CYP2D6—Vinblastine—breast cancer	0.0178	0.125	CbGbCtD
Methylnaltrexone—CYP2D6—Doxorubicin—breast cancer	0.0109	0.0766	CbGbCtD
Methylnaltrexone—Gastrointestinal pain—Ixabepilone—breast cancer	0.000988	0.00414	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—breast cancer	0.000984	0.00412	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Letrozole—breast cancer	0.000982	0.00411	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Anastrozole—breast cancer	0.000982	0.00411	CcSEcCtD
Methylnaltrexone—Dizziness—Fulvestrant—breast cancer	0.000975	0.00408	CcSEcCtD
Methylnaltrexone—Pain—Letrozole—breast cancer	0.000973	0.00408	CcSEcCtD
Methylnaltrexone—Pain—Anastrozole—breast cancer	0.000973	0.00408	CcSEcCtD
Methylnaltrexone—Dizziness—Toremifene—breast cancer	0.000962	0.00403	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ixabepilone—breast cancer	0.000955	0.004	CcSEcCtD
Methylnaltrexone—Erythema—Tamoxifen—breast cancer	0.000954	0.004	CcSEcCtD
Methylnaltrexone—Nausea—Lapatinib—breast cancer	0.000952	0.00399	CcSEcCtD
Methylnaltrexone—Vomiting—Fulvestrant—breast cancer	0.000937	0.00393	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Raloxifene—breast cancer	0.000932	0.00391	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Anastrozole—breast cancer	0.00093	0.0039	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Letrozole—breast cancer	0.00093	0.0039	CcSEcCtD
Methylnaltrexone—Vomiting—Toremifene—breast cancer	0.000925	0.00388	CcSEcCtD
Methylnaltrexone—Pain—Raloxifene—breast cancer	0.000923	0.00387	CcSEcCtD
Methylnaltrexone—Erythema—Goserelin—breast cancer	0.000911	0.00382	CcSEcCtD
Methylnaltrexone—Abdominal pain—Anastrozole—breast cancer	0.000899	0.00377	CcSEcCtD
Methylnaltrexone—Abdominal pain—Letrozole—breast cancer	0.000899	0.00377	CcSEcCtD
Methylnaltrexone—Flatulence—Goserelin—breast cancer	0.000898	0.00376	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—breast cancer	0.000886	0.00371	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Raloxifene—breast cancer	0.000883	0.0037	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Idarubicin—breast cancer	0.000883	0.0037	CcSEcCtD
Methylnaltrexone—Diarrhoea—Exemestane—breast cancer	0.000876	0.00367	CcSEcCtD
Methylnaltrexone—Nausea—Fulvestrant—breast cancer	0.000876	0.00367	CcSEcCtD
Methylnaltrexone—Nausea—Toremifene—breast cancer	0.000864	0.00362	CcSEcCtD
Methylnaltrexone—Abdominal pain—Raloxifene—breast cancer	0.000854	0.00358	CcSEcCtD
Methylnaltrexone—Abdominal pain—Idarubicin—breast cancer	0.000854	0.00358	CcSEcCtD
Methylnaltrexone—Dizziness—Exemestane—breast cancer	0.000847	0.00355	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ixabepilone—breast cancer	0.000827	0.00346	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—breast cancer	0.00082	0.00343	CcSEcCtD
Methylnaltrexone—Erythema—Vinorelbine—breast cancer	0.000816	0.00342	CcSEcCtD
Methylnaltrexone—Vomiting—Exemestane—breast cancer	0.000814	0.00341	CcSEcCtD
Methylnaltrexone—Dizziness—Ixabepilone—breast cancer	0.000799	0.00335	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—breast cancer	0.00079	0.00331	CcSEcCtD
Methylnaltrexone—Erythema—Thiotepa—breast cancer	0.000779	0.00326	CcSEcCtD
Methylnaltrexone—Oedema—Tamoxifen—breast cancer	0.000779	0.00326	CcSEcCtD
Methylnaltrexone—Diarrhoea—Letrozole—breast cancer	0.000779	0.00326	CcSEcCtD
Methylnaltrexone—Diarrhoea—Anastrozole—breast cancer	0.000779	0.00326	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—breast cancer	0.00077	0.00323	CcSEcCtD
Methylnaltrexone—Vomiting—Ixabepilone—breast cancer	0.000768	0.00322	CcSEcCtD
Methylnaltrexone—Oedema—Melphalan—breast cancer	0.000762	0.00319	CcSEcCtD
Methylnaltrexone—Nausea—Exemestane—breast cancer	0.000761	0.00319	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Chlorambucil—breast cancer	0.000755	0.00316	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Tamoxifen—breast cancer	0.000753	0.00315	CcSEcCtD
Methylnaltrexone—Dizziness—Letrozole—breast cancer	0.000752	0.00315	CcSEcCtD
Methylnaltrexone—Dizziness—Anastrozole—breast cancer	0.000752	0.00315	CcSEcCtD
Methylnaltrexone—Pain—Chlorambucil—breast cancer	0.000748	0.00313	CcSEcCtD
Methylnaltrexone—Oedema—Goserelin—breast cancer	0.000744	0.00312	CcSEcCtD
Methylnaltrexone—Skin disorder—Melphalan—breast cancer	0.000741	0.0031	CcSEcCtD
Methylnaltrexone—Diarrhoea—Idarubicin—breast cancer	0.000739	0.0031	CcSEcCtD
Methylnaltrexone—Diarrhoea—Raloxifene—breast cancer	0.000739	0.0031	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Goserelin—breast cancer	0.000729	0.00306	CcSEcCtD
Methylnaltrexone—Vomiting—Letrozole—breast cancer	0.000723	0.00303	CcSEcCtD
Methylnaltrexone—Vomiting—Anastrozole—breast cancer	0.000723	0.00303	CcSEcCtD
Methylnaltrexone—Skin disorder—Goserelin—breast cancer	0.000722	0.00303	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Goserelin—breast cancer	0.000719	0.00301	CcSEcCtD
Methylnaltrexone—Nausea—Ixabepilone—breast cancer	0.000718	0.00301	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Chlorambucil—breast cancer	0.000715	0.003	CcSEcCtD
Methylnaltrexone—Dizziness—Raloxifene—breast cancer	0.000714	0.00299	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—breast cancer	0.000714	0.00299	CcSEcCtD
Methylnaltrexone—Abdominal pain—Chlorambucil—breast cancer	0.000691	0.0029	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.00069	0.00289	CcSEcCtD
Methylnaltrexone—Vomiting—Idarubicin—breast cancer	0.000687	0.00288	CcSEcCtD
Methylnaltrexone—Vomiting—Raloxifene—breast cancer	0.000687	0.00288	CcSEcCtD
Methylnaltrexone—Pain—Vinblastine—breast cancer	0.000685	0.00287	CcSEcCtD
Methylnaltrexone—Nausea—Letrozole—breast cancer	0.000676	0.00283	CcSEcCtD
Methylnaltrexone—Nausea—Anastrozole—breast cancer	0.000676	0.00283	CcSEcCtD
Methylnaltrexone—Erythema—Mitoxantrone—breast cancer	0.000673	0.00282	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000672	0.00282	CcSEcCtD
Methylnaltrexone—Pain—Tamoxifen—breast cancer	0.000666	0.00279	CcSEcCtD
Methylnaltrexone—Flatulence—Irinotecan—breast cancer	0.000663	0.00278	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—breast cancer	0.00066	0.00277	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.000659	0.00276	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Melphalan—breast cancer	0.000658	0.00276	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCG2—breast cancer	0.000657	0.0891	CrCbGaD
Methylnaltrexone—Erythema—Gemcitabine—breast cancer	0.000656	0.00275	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinblastine—breast cancer	0.000655	0.00275	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vinorelbine—breast cancer	0.000653	0.00274	CcSEcCtD
Methylnaltrexone—Pain—Melphalan—breast cancer	0.000652	0.00273	CcSEcCtD
Methylnaltrexone—Skin disorder—Vinorelbine—breast cancer	0.000647	0.00271	CcSEcCtD
Methylnaltrexone—Erythema—Fluorouracil—breast cancer	0.000645	0.0027	CcSEcCtD
Methylnaltrexone—Nausea—Idarubicin—breast cancer	0.000641	0.00269	CcSEcCtD
Methylnaltrexone—Nausea—Raloxifene—breast cancer	0.000641	0.00269	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—breast cancer	0.000639	0.0866	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Tamoxifen—breast cancer	0.000637	0.00267	CcSEcCtD
Methylnaltrexone—Pain—Goserelin—breast cancer	0.000636	0.00266	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinblastine—breast cancer	0.000634	0.00265	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Thiotepa—breast cancer	0.000624	0.00261	CcSEcCtD
Methylnaltrexone—Skin disorder—Thiotepa—breast cancer	0.000618	0.00259	CcSEcCtD
Methylnaltrexone—Abdominal pain—Tamoxifen—breast cancer	0.000616	0.00258	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Goserelin—breast cancer	0.000608	0.00255	CcSEcCtD
Methylnaltrexone—Diarrhoea—Chlorambucil—breast cancer	0.000598	0.00251	CcSEcCtD
Methylnaltrexone—Abdominal pain—Goserelin—breast cancer	0.000588	0.00246	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000575	0.00241	CcSEcCtD
Methylnaltrexone—Pain—Vinorelbine—breast cancer	0.00057	0.00239	CcSEcCtD
Methylnaltrexone—Vomiting—Chlorambucil—breast cancer	0.000556	0.00233	CcSEcCtD
Methylnaltrexone—Hydromorphone—PTGS1—breast cancer	0.000555	0.0752	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.000554	0.00232	CcSEcCtD
Methylnaltrexone—Oedema—Irinotecan—breast cancer	0.000549	0.0023	CcSEcCtD
Methylnaltrexone—Oedema—Mitoxantrone—breast cancer	0.000549	0.0023	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Thiotepa—breast cancer	0.000549	0.0023	CcSEcCtD
Methylnaltrexone—Erythema—Paclitaxel—breast cancer	0.000549	0.0023	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinblastine—breast cancer	0.000548	0.0023	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinorelbine—breast cancer	0.000545	0.00228	CcSEcCtD
Methylnaltrexone—Pain—Thiotepa—breast cancer	0.000544	0.00228	CcSEcCtD
Methylnaltrexone—Flatulence—Paclitaxel—breast cancer	0.000541	0.00227	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Irinotecan—breast cancer	0.000539	0.00226	CcSEcCtD
Methylnaltrexone—Oedema—Gemcitabine—breast cancer	0.000535	0.00224	CcSEcCtD
Methylnaltrexone—Skin disorder—Mitoxantrone—breast cancer	0.000534	0.00224	CcSEcCtD
Methylnaltrexone—Diarrhoea—Tamoxifen—breast cancer	0.000533	0.00223	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Irinotecan—breast cancer	0.000531	0.00222	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mitoxantrone—breast cancer	0.000531	0.00222	CcSEcCtD
Methylnaltrexone—Dizziness—Vinblastine—breast cancer	0.00053	0.00222	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinorelbine—breast cancer	0.000527	0.00221	CcSEcCtD
Methylnaltrexone—Oedema—Fluorouracil—breast cancer	0.000526	0.0022	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gemcitabine—breast cancer	0.000525	0.0022	CcSEcCtD
Methylnaltrexone—Diarrhoea—Melphalan—breast cancer	0.000522	0.00219	CcSEcCtD
Methylnaltrexone—Oxymorphone—CYP2D6—breast cancer	0.000521	0.0706	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Thiotepa—breast cancer	0.00052	0.00218	CcSEcCtD
Methylnaltrexone—Skin disorder—Gemcitabine—breast cancer	0.00052	0.00218	CcSEcCtD
Methylnaltrexone—Nausea—Chlorambucil—breast cancer	0.00052	0.00218	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gemcitabine—breast cancer	0.000517	0.00217	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fluorouracil—breast cancer	0.000516	0.00216	CcSEcCtD
Methylnaltrexone—Dizziness—Tamoxifen—breast cancer	0.000515	0.00216	CcSEcCtD
Methylnaltrexone—Vomiting—Vinblastine—breast cancer	0.00051	0.00213	CcSEcCtD
Methylnaltrexone—Diarrhoea—Goserelin—breast cancer	0.000509	0.00213	CcSEcCtD
Methylnaltrexone—Abdominal pain—Thiotepa—breast cancer	0.000503	0.00211	CcSEcCtD
Methylnaltrexone—Vomiting—Tamoxifen—breast cancer	0.000495	0.00207	CcSEcCtD
Methylnaltrexone—Dizziness—Goserelin—breast cancer	0.000492	0.00206	CcSEcCtD
Methylnaltrexone—Vomiting—Melphalan—breast cancer	0.000485	0.00203	CcSEcCtD
Methylnaltrexone—Nausea—Vinblastine—breast cancer	0.000476	0.00199	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Irinotecan—breast cancer	0.000474	0.00199	CcSEcCtD
Methylnaltrexone—Vomiting—Goserelin—breast cancer	0.000473	0.00198	CcSEcCtD
Methylnaltrexone—Pain—Mitoxantrone—breast cancer	0.00047	0.00197	CcSEcCtD
Methylnaltrexone—Pain—Irinotecan—breast cancer	0.00047	0.00197	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—breast cancer	0.000465	0.00195	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000464	0.00194	CcSEcCtD
Methylnaltrexone—Nausea—Tamoxifen—breast cancer	0.000463	0.00194	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000462	0.00194	CcSEcCtD
Methylnaltrexone—Pain—Gemcitabine—breast cancer	0.000458	0.00192	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinorelbine—breast cancer	0.000456	0.00191	CcSEcCtD
Methylnaltrexone—Hydrocodone—CYP2D6—breast cancer	0.000456	0.0617	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000454	0.0019	CcSEcCtD
Methylnaltrexone—Nausea—Melphalan—breast cancer	0.000453	0.0019	CcSEcCtD
Methylnaltrexone—Erythema—Capecitabine—breast cancer	0.00045	0.00189	CcSEcCtD
Methylnaltrexone—Pain—Fluorouracil—breast cancer	0.00045	0.00188	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000449	0.00188	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Irinotecan—breast cancer	0.000449	0.00188	CcSEcCtD
Methylnaltrexone—Oedema—Paclitaxel—breast cancer	0.000448	0.00188	CcSEcCtD
Methylnaltrexone—Oxymorphone—CYP3A4—breast cancer	0.000447	0.0606	CrCbGaD
Methylnaltrexone—Flatulence—Capecitabine—breast cancer	0.000444	0.00186	CcSEcCtD
Methylnaltrexone—Nausea—Goserelin—breast cancer	0.000442	0.00185	CcSEcCtD
Methylnaltrexone—Dizziness—Vinorelbine—breast cancer	0.00044	0.00185	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Paclitaxel—breast cancer	0.000439	0.00184	CcSEcCtD
Methylnaltrexone—Diarrhoea—Thiotepa—breast cancer	0.000435	0.00182	CcSEcCtD
Methylnaltrexone—Skin disorder—Paclitaxel—breast cancer	0.000435	0.00182	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mitoxantrone—breast cancer	0.000434	0.00182	CcSEcCtD
Methylnaltrexone—Abdominal pain—Irinotecan—breast cancer	0.000434	0.00182	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Paclitaxel—breast cancer	0.000433	0.00181	CcSEcCtD
Methylnaltrexone—Vomiting—Vinorelbine—breast cancer	0.000424	0.00177	CcSEcCtD
Methylnaltrexone—Dizziness—Thiotepa—breast cancer	0.000421	0.00176	CcSEcCtD
Methylnaltrexone—Oxycodone—CYP2D6—breast cancer	0.000416	0.0563	CrCbGaD
Methylnaltrexone—Vomiting—Thiotepa—breast cancer	0.000404	0.00169	CcSEcCtD
Methylnaltrexone—Nausea—Vinorelbine—breast cancer	0.000396	0.00166	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000393	0.00165	CcSEcCtD
Methylnaltrexone—Hydrocodone—CYP3A4—breast cancer	0.000391	0.053	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000387	0.00162	CcSEcCtD
Methylnaltrexone—Pain—Paclitaxel—breast cancer	0.000383	0.0016	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2D6—breast cancer	0.000383	0.0519	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000381	0.0016	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—breast cancer	0.00038	0.00159	CcSEcCtD
Methylnaltrexone—Nausea—Thiotepa—breast cancer	0.000378	0.00158	CcSEcCtD
Methylnaltrexone—Hydromorphone—CYP2D6—breast cancer	0.000378	0.0512	CrCbGaD
Methylnaltrexone—Diarrhoea—Irinotecan—breast cancer	0.000376	0.00157	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mitoxantrone—breast cancer	0.000376	0.00157	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—breast cancer	0.000372	0.00156	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—breast cancer	0.000372	0.0504	CrCbGaD
Methylnaltrexone—Skin disorder—Docetaxel—breast cancer	0.000369	0.00155	CcSEcCtD
Methylnaltrexone—Oedema—Capecitabine—breast cancer	0.000368	0.00154	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Paclitaxel—breast cancer	0.000366	0.00153	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gemcitabine—breast cancer	0.000366	0.00153	CcSEcCtD
Methylnaltrexone—Dizziness—Irinotecan—breast cancer	0.000363	0.00152	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Capecitabine—breast cancer	0.000361	0.00151	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fluorouracil—breast cancer	0.00036	0.00151	CcSEcCtD
Methylnaltrexone—Skin disorder—Capecitabine—breast cancer	0.000357	0.0015	CcSEcCtD
Methylnaltrexone—Oxycodone—CYP3A4—breast cancer	0.000357	0.0483	CrCbGaD
Methylnaltrexone—Hyperhidrosis—Capecitabine—breast cancer	0.000355	0.00149	CcSEcCtD
Methylnaltrexone—Abdominal pain—Paclitaxel—breast cancer	0.000354	0.00148	CcSEcCtD
Methylnaltrexone—Vomiting—Irinotecan—breast cancer	0.000349	0.00146	CcSEcCtD
Methylnaltrexone—Vomiting—Mitoxantrone—breast cancer	0.000349	0.00146	CcSEcCtD
Methylnaltrexone—Dizziness—Fluorouracil—breast cancer	0.000348	0.00146	CcSEcCtD
Methylnaltrexone—Vomiting—Gemcitabine—breast cancer	0.00034	0.00143	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—breast cancer	0.000335	0.0014	CcSEcCtD
Methylnaltrexone—Vomiting—Fluorouracil—breast cancer	0.000335	0.0014	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP3A4—breast cancer	0.000329	0.0445	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—breast cancer	0.000328	0.00137	CcSEcCtD
Methylnaltrexone—Nausea—Mitoxantrone—breast cancer	0.000326	0.00137	CcSEcCtD
Methylnaltrexone—Nausea—Irinotecan—breast cancer	0.000326	0.00137	CcSEcCtD
Methylnaltrexone—Naloxone—CYP3A4—breast cancer	0.000326	0.0442	CrCbGaD
Methylnaltrexone—Pain—Docetaxel—breast cancer	0.000325	0.00136	CcSEcCtD
Methylnaltrexone—Hydromorphone—CYP3A4—breast cancer	0.000324	0.0439	CrCbGaD
Methylnaltrexone—Nausea—Gemcitabine—breast cancer	0.000318	0.00133	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Capecitabine—breast cancer	0.000317	0.00133	CcSEcCtD
Methylnaltrexone—Pain—Capecitabine—breast cancer	0.000314	0.00132	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—breast cancer	0.000314	0.00131	CcSEcCtD
Methylnaltrexone—Nausea—Fluorouracil—breast cancer	0.000313	0.00131	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—breast cancer	0.000311	0.0013	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—breast cancer	0.000309	0.0013	CcSEcCtD
Methylnaltrexone—Diarrhoea—Paclitaxel—breast cancer	0.000307	0.00128	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Capecitabine—breast cancer	0.000301	0.00126	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—breast cancer	0.0003	0.00126	CcSEcCtD
Methylnaltrexone—Dizziness—Paclitaxel—breast cancer	0.000296	0.00124	CcSEcCtD
Methylnaltrexone—Abdominal pain—Capecitabine—breast cancer	0.000291	0.00122	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—breast cancer	0.00029	0.00122	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—breast cancer	0.000286	0.0012	CcSEcCtD
Methylnaltrexone—Vomiting—Paclitaxel—breast cancer	0.000285	0.00119	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—breast cancer	0.000285	0.0386	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000284	0.00119	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—breast cancer	0.000274	0.0371	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—breast cancer	0.000272	0.0368	CrCbGaD
Methylnaltrexone—Nervous system disorder—Methotrexate—breast cancer	0.000268	0.00112	CcSEcCtD
Methylnaltrexone—Nausea—Paclitaxel—breast cancer	0.000266	0.00111	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—breast cancer	0.000266	0.00111	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000265	0.00111	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—breast cancer	0.000265	0.00111	CcSEcCtD
Methylnaltrexone—Diarrhoea—Docetaxel—breast cancer	0.00026	0.00109	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—breast cancer	0.000256	0.00107	CcSEcCtD
Methylnaltrexone—Diarrhoea—Capecitabine—breast cancer	0.000252	0.00105	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—breast cancer	0.000251	0.00105	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—breast cancer	0.000251	0.00105	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—breast cancer	0.000249	0.00104	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—breast cancer	0.000248	0.00104	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000246	0.00103	CcSEcCtD
Methylnaltrexone—Dizziness—Capecitabine—breast cancer	0.000243	0.00102	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—breast cancer	0.000241	0.00101	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—breast cancer	0.000237	0.000993	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—breast cancer	0.000236	0.00099	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—breast cancer	0.000234	0.00098	CcSEcCtD
Methylnaltrexone—Vomiting—Capecitabine—breast cancer	0.000234	0.000979	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—breast cancer	0.000232	0.000974	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—breast cancer	0.00023	0.000964	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—breast cancer	0.000229	0.00096	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—breast cancer	0.000226	0.000945	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—breast cancer	0.000224	0.000938	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—breast cancer	0.000221	0.000926	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—breast cancer	0.000219	0.000918	CcSEcCtD
Methylnaltrexone—Nausea—Capecitabine—breast cancer	0.000218	0.000915	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—breast cancer	0.000216	0.000906	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—breast cancer	0.000209	0.000877	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000205	0.000857	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—breast cancer	0.000203	0.000849	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—breast cancer	0.000202	0.000848	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—breast cancer	0.000194	0.000812	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—breast cancer	0.000187	0.000785	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—breast cancer	0.000187	0.000784	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—breast cancer	0.000181	0.000758	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—breast cancer	0.000175	0.000734	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—breast cancer	0.000174	0.000729	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—breast cancer	0.000169	0.000709	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—breast cancer	0.000163	0.000682	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—breast cancer	0.000163	0.000681	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—breast cancer	0.000162	0.000679	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—breast cancer	0.000157	0.000656	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—breast cancer	0.000152	0.000637	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—breast cancer	0.000151	0.000631	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—breast cancer	0.000141	0.00059	CcSEcCtD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL12—breast cancer	2.57e-05	0.000342	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—breast cancer	2.55e-05	0.000339	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFA—breast cancer	2.54e-05	0.000339	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PAK1—breast cancer	2.52e-05	0.000336	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—breast cancer	2.51e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TCF7L2—breast cancer	2.48e-05	0.00033	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITPR1—breast cancer	2.47e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT2—breast cancer	2.47e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCC1—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA3—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMMR—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB4—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT5A—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP3—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—breast cancer	2.45e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—breast cancer	2.44e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HSP90AA1—breast cancer	2.39e-05	0.000318	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH2—breast cancer	2.39e-05	0.000318	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARGC1B—breast cancer	2.37e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SMAD4—breast cancer	2.37e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—breast cancer	2.37e-05	0.000315	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1R—breast cancer	2.36e-05	0.000314	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—breast cancer	2.35e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGTR1—breast cancer	2.32e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRL—breast cancer	2.32e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—breast cancer	2.32e-05	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NCOR1—breast cancer	2.3e-05	0.000307	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLA2G4A—breast cancer	2.3e-05	0.000307	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STK11—breast cancer	2.29e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADAM10—breast cancer	2.29e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSF2—breast cancer	2.28e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF1—breast cancer	2.28e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RAF1—breast cancer	2.27e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLG—breast cancer	2.26e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRG1—breast cancer	2.26e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—H2AFX—breast cancer	2.24e-05	0.000299	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—breast cancer	2.24e-05	0.000299	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CA9—breast cancer	2.24e-05	0.000298	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA4—breast cancer	2.24e-05	0.000298	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT2—breast cancer	2.24e-05	0.000298	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—E2F1—breast cancer	2.23e-05	0.000297	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF10—breast cancer	2.23e-05	0.000297	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—breast cancer	2.22e-05	0.000295	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX2—breast cancer	2.18e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA2—breast cancer	2.18e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX4—breast cancer	2.16e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT1A1—breast cancer	2.16e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—breast cancer	2.15e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFA—breast cancer	2.15e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPP1—breast cancer	2.14e-05	0.000285	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—breast cancer	2.13e-05	0.000284	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—breast cancer	2.12e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB3—breast cancer	2.12e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR2—breast cancer	2.11e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA1—breast cancer	2.11e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—IDH1—breast cancer	2.11e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITPR1—breast cancer	2.08e-05	0.000278	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAT2—breast cancer	2.08e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB4—breast cancer	2.07e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT5A—breast cancer	2.07e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP3—breast cancer	2.07e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—breast cancer	2.06e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—breast cancer	2.04e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—breast cancer	2.03e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SMAD4—breast cancer	2.01e-05	0.000267	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1R—breast cancer	1.99e-05	0.000265	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—breast cancer	1.98e-05	0.000264	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR1—breast cancer	1.97e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—breast cancer	1.96e-05	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLA2G4A—breast cancer	1.95e-05	0.000259	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NCOR1—breast cancer	1.95e-05	0.000259	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—breast cancer	1.94e-05	0.000258	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF1—breast cancer	1.92e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSF2—breast cancer	1.92e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RAF1—breast cancer	1.92e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRG1—breast cancer	1.91e-05	0.000254	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—H2AFX—breast cancer	1.9e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—breast cancer	1.9e-05	0.000252	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—breast cancer	1.9e-05	0.000252	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—E2F1—breast cancer	1.88e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CAV1—breast cancer	1.88e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—breast cancer	1.87e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—breast cancer	1.86e-05	0.000247	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DPYD—breast cancer	1.83e-05	0.000243	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MED12—breast cancer	1.83e-05	0.000243	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPP1—breast cancer	1.81e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—breast cancer	1.81e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—breast cancer	1.8e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDOA—breast cancer	1.8e-05	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB3—breast cancer	1.79e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR2—breast cancer	1.79e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FN1—breast cancer	1.79e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKBIA—breast cancer	1.77e-05	0.000235	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—breast cancer	1.75e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA3—breast cancer	1.75e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A2—breast cancer	1.73e-05	0.000231	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—breast cancer	1.72e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—breast cancer	1.72e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—breast cancer	1.71e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KIT—breast cancer	1.71e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APC—breast cancer	1.71e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CPT1A—breast cancer	1.7e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTR—breast cancer	1.7e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG2—breast cancer	1.7e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—breast cancer	1.69e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HPGDS—breast cancer	1.67e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR1—breast cancer	1.67e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HBA1—breast cancer	1.66e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—breast cancer	1.64e-05	0.000218	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK3—breast cancer	1.64e-05	0.000218	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACHE—breast cancer	1.62e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—breast cancer	1.62e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BRAF—breast cancer	1.61e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—breast cancer	1.6e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CAV1—breast cancer	1.59e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—breast cancer	1.57e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—breast cancer	1.57e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT2—breast cancer	1.56e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—breast cancer	1.56e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP17A1—breast cancer	1.53e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—breast cancer	1.53e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENO1—breast cancer	1.51e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS1—breast cancer	1.51e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FN1—breast cancer	1.51e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—breast cancer	1.5e-05	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKBIA—breast cancer	1.49e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—breast cancer	1.49e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—breast cancer	1.49e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—breast cancer	1.48e-05	0.000197	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—breast cancer	1.47e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA2—breast cancer	1.46e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KIT—breast cancer	1.45e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APC—breast cancer	1.45e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—breast cancer	1.45e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—breast cancer	1.43e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—breast cancer	1.42e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FASN—breast cancer	1.41e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCHE—breast cancer	1.41e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A5—breast cancer	1.39e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK3—breast cancer	1.38e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BRAF—breast cancer	1.36e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—breast cancer	1.35e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—breast cancer	1.35e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—breast cancer	1.34e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A1—breast cancer	1.34e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAF1—breast cancer	1.34e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RELA—breast cancer	1.34e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—breast cancer	1.33e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—breast cancer	1.32e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT2—breast cancer	1.32e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—breast cancer	1.32e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTOR—breast cancer	1.31e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—breast cancer	1.31e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP3A4—breast cancer	1.31e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1B1—breast cancer	1.29e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—breast cancer	1.27e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.26e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—breast cancer	1.26e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	1.26e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—breast cancer	1.26e-05	0.000167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HRAS—breast cancer	1.25e-05	0.000167	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—breast cancer	1.24e-05	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1B—breast cancer	1.23e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA1—breast cancer	1.23e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—breast cancer	1.22e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STK11—breast cancer	1.21e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP19A1—breast cancer	1.21e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—breast cancer	1.21e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—breast cancer	1.2e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—breast cancer	1.2e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—breast cancer	1.2e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—breast cancer	1.17e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUN—breast cancer	1.17e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CTNNB1—breast cancer	1.16e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	1.14e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—breast cancer	1.14e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—breast cancer	1.14e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAF1—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RELA—breast cancer	1.13e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COMT—breast cancer	1.13e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—breast cancer	1.12e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—breast cancer	1.12e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK8—breast cancer	1.11e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—breast cancer	1.11e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTOR—breast cancer	1.11e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—breast cancer	1.1e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—breast cancer	1.1e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ITPR1—breast cancer	1.1e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—breast cancer	1.06e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—breast cancer	1.06e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HRAS—breast cancer	1.06e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—breast cancer	1.05e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMS—breast cancer	1.04e-05	0.000139	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1B—breast cancer	1.04e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.03e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOR1—breast cancer	1.03e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—breast cancer	1.03e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—breast cancer	1.03e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—breast cancer	1.02e-05	0.000136	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—breast cancer	1.02e-05	0.000136	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—breast cancer	1.02e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—breast cancer	1.01e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—breast cancer	1.01e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—breast cancer	9.92e-06	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUN—breast cancer	9.89e-06	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—breast cancer	9.86e-06	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CTNNB1—breast cancer	9.82e-06	0.000131	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1A1—breast cancer	9.76e-06	0.00013	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ERCC2—breast cancer	9.68e-06	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK3—breast cancer	9.68e-06	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—breast cancer	9.63e-06	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—breast cancer	9.59e-06	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—breast cancer	9.57e-06	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—breast cancer	9.41e-06	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—breast cancer	9.39e-06	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK8—breast cancer	9.36e-06	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—breast cancer	9.34e-06	0.000124	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—breast cancer	9.2e-06	0.000123	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—breast cancer	9.1e-06	0.000121	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—breast cancer	8.88e-06	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—breast cancer	8.7e-06	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—breast cancer	8.64e-06	0.000115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—breast cancer	8.56e-06	0.000114	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAV1—breast cancer	8.39e-06	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK3—breast cancer	8.18e-06	0.000109	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—breast cancer	7.99e-06	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—breast cancer	7.95e-06	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—breast cancer	7.93e-06	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—breast cancer	7.78e-06	0.000104	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—breast cancer	7.73e-06	0.000103	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—breast cancer	7.64e-06	0.000102	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRAS—breast cancer	7.39e-06	9.84e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—breast cancer	7.35e-06	9.78e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—breast cancer	7.07e-06	9.42e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—breast cancer	6.75e-06	8.99e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—breast cancer	6.72e-06	8.94e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—breast cancer	6.63e-06	8.83e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—breast cancer	6.53e-06	8.7e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—breast cancer	6.53e-06	8.69e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—breast cancer	6.34e-06	8.45e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRAS—breast cancer	6.25e-06	8.32e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—breast cancer	5.98e-06	7.96e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—breast cancer	5.86e-06	7.8e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—breast cancer	5.8e-06	7.72e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—breast cancer	5.52e-06	7.34e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—breast cancer	5.06e-06	6.74e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—breast cancer	3.57e-06	4.75e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—breast cancer	2.92e-06	3.88e-05	CbGpPWpGaD
